rs113488022
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Genetic analyses revealed amplification of the BRAF gene in both the primary cerebellar pilocytic astrocytoma and the recurrent tumor with biphasic features, as well as a BRAF V600E missense mutation in the oligodendroglioma-like component.
|
23082883 |
2013 |
rs113488022
|
|
|
0.030 |
GeneticVariation |
BEFREE |
A BRAF(V600E) mutation was also detected in one oligodendroglioma, and a BRAF(A598V) in one diffuse astrocytoma.
|
22568401 |
2012 |
rs113488022
|
|
|
0.030 |
GeneticVariation |
BEFREE |
BRAF V600E mutant oligodendroglioma-like tumors with chromosomal instability in adolescents and young adults.
|
31630459 |
2019 |
rs121913377
|
|
|
0.030 |
GeneticVariation |
BEFREE |
A BRAF(V600E) mutation was also detected in one oligodendroglioma, and a BRAF(A598V) in one diffuse astrocytoma.
|
22568401 |
2012 |
rs121913377
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Genetic analyses revealed amplification of the BRAF gene in both the primary cerebellar pilocytic astrocytoma and the recurrent tumor with biphasic features, as well as a BRAF V600E missense mutation in the oligodendroglioma-like component.
|
23082883 |
2013 |
rs121913377
|
|
|
0.030 |
GeneticVariation |
BEFREE |
BRAF V600E mutant oligodendroglioma-like tumors with chromosomal instability in adolescents and young adults.
|
31630459 |
2019 |
rs55705857
|
|
|
0.010 |
GeneticVariation |
BEFREE |
First-degree relatives of rs55705857 G allele carriers were at significantly increased risk for developing cancer (RR = 1.72, p = 0.045, CI 1.02-2.94), and specifically for oligodendroglioma (RR = 57.61, p = 0.017, CI 2.96-320.98) or prostate cancer (RR = 4.10, p = 0.008, CI 1.62-9.58); relatives of individuals without the G allele were not at increased risk.
|
30823903 |
2019 |
rs11133391
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The variant allele for CLOCK rs11133391 under a recessive model increased risk of oligodendroglioma (OR 2.41; 95 % CI 1.31-4.42; p = 0.005), though not other glioma subtypes (p for heterogeneity = 0.0033).
|
24135790 |
2014 |
rs121913500
|
|
|
0.080 |
GeneticVariation |
BEFREE |
This glioma xenograft is the first to display a pure oligodendroglioma histology and expression of R132H.
|
23527265 |
2013 |
rs121913500
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG.
|
24252742 |
2013 |
rs121913500
|
|
|
0.080 |
GeneticVariation |
BEFREE |
The reported two cases were initially diagnosed as oligodendroglioma with 1p/19q-codeletion and mutation of <i>isocitrate dehydrogenase 1 (IDH1)</i>-R132H.
|
31508376 |
2019 |
rs121913500
|
|
|
0.080 |
GeneticVariation |
BEFREE |
ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
|
25427834 |
2015 |
rs121913500
|
|
|
0.080 |
GeneticVariation |
BEFREE |
The mutation analysis performed on the latter case with DNA separately sampled from the oligodendroglioma- like area and the astrocytoma-like area detected IDH1 G395A in both areas.
|
22385787 |
2012 |
rs121913500
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Three GBM-O samples had IDH1 (p.R132H) mutations; two of these also demonstrated 1p/19q co-deletion and had a proneural transcriptional profile, a molecular signature characteristic of oligodendroglioma.
|
26757882 |
2016 |
rs121913500
|
|
|
0.080 |
GeneticVariation |
BEFREE |
The histopathological findings of his surgical specimen revealed characteristics of a low-grade glioma with an IDH1 c.395G>A (R132H) mutation and 1p/19q codeletion, which led to a definitive diagnosis of oligodendroglioma.
|
29224049 |
2018 |
rs121913500
|
|
|
0.080 |
GeneticVariation |
BEFREE |
We evaluated nuclear cMYC protein levels and IDH1 (R132H) by immunohistochemistry in patients with oligodendroglioma/oligoastrocytomas (n = 20), astrocytomas (grade II) (n = 19), anaplastic astrocytomas (n = 21) or glioblastomas (n = 111).
|
23934175 |
2013 |
rs118101777
|
|
|
0.030 |
GeneticVariation |
BEFREE |
ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
|
25427834 |
2015 |
rs118101777
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG.
|
24252742 |
2013 |
rs118101777
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Three GBM-O samples had IDH1 (p.R132H) mutations; two of these also demonstrated 1p/19q co-deletion and had a proneural transcriptional profile, a molecular signature characteristic of oligodendroglioma.
|
26757882 |
2016 |
rs121913503
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A c.515G>T (p.R172M) mutation of the IDH2 gene was only identified in a grade II oligodendroglioma patient which was wild-type for IDH1.
|
21643842 |
2011 |
rs1034749666
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Molecular cytogenetic analyses demonstrated chromosomal losses of 1p and 19q and a mutation of isocitrate dehydrogenase 1 (G395A, R132H) in both the oligodendroglioma and gangliocytoma areas.
|
24054724 |
2013 |
rs587777627
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In addition to the POLE p.L424V recurrent mutation in a patient with polyposis, CRC and oligodendroglioma, six novel or rare POLD1 variants (four of them, p.D316H, p.D316G, p.R409W, and p.L474P, with strong evidence for pathogenicity) were identified in nonpolyposis CRC families.
|
26133394 |
2016 |
rs483352909
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In addition to the POLE p.L424V recurrent mutation in a patient with polyposis, CRC and oligodendroglioma, six novel or rare POLD1 variants (four of them, p.D316H, p.D316G, p.R409W, and p.L474P, with strong evidence for pathogenicity) were identified in nonpolyposis CRC families.
|
26133394 |
2016 |
rs2296212
|
|
|
0.010 |
GeneticVariation |
BEFREE |
However, analyses according to histological subtypes revealed a statistically significant increased risk of oligodendroglioma in association with SMARCA2 rs2296212 (OR = 4.05, 95% CI = 1.11-14.80, P = 0.030, q = 0.08) and rs4741651 (OR = 4.68, 95% CI = 1.43-15.30, P = 0.011, q = 0.08) and SMARCA4 rs11672232 (OR = 1.90, 95% CI = 1.01-3.58, P = 0.048, q = 0.08) and rs12232780 (OR = 2.14, 95% CI = 1.06-4.33, P = 0.035, q = 0.08).
|
23276717 |
2013 |
rs4741651
|
|
|
0.010 |
GeneticVariation |
BEFREE |
However, analyses according to histological subtypes revealed a statistically significant increased risk of oligodendroglioma in association with SMARCA2 rs2296212 (OR = 4.05, 95% CI = 1.11-14.80, P = 0.030, q = 0.08) and rs4741651 (OR = 4.68, 95% CI = 1.43-15.30, P = 0.011, q = 0.08) and SMARCA4 rs11672232 (OR = 1.90, 95% CI = 1.01-3.58, P = 0.048, q = 0.08) and rs12232780 (OR = 2.14, 95% CI = 1.06-4.33, P = 0.035, q = 0.08).
|
23276717 |
2013 |